• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#361 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 03 December 2013 - 09:56 AM

Asterias Biotherapeutics Inc files registration statement for public offering ...
MENAFN.COM - 2 hours ago
Asterias Biotherapeutics Inc is a subsidiary of BioTime Inc (nyse mkt:BTX), a biotechnology company engaged in research and product development in the field of regenerative medicine.

View the full article

#362 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 04 December 2013 - 01:52 PM

BioTime, Inc. : BioTime's CEO, Dr. Michael West to Moderate Session on ...
4-traders (press release) - 2 hours ago
BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr. Michael West will lead a session titled "From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative" today at the ...

View the full article

#363 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 04 December 2013 - 01:52 PM

BioTime, Inc. : BioTime's CEO, Dr. Michael West to Moderate Session on ...
4-traders (press release) - 9 hours ago
BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr. Michael West will lead a session titled "From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative" today at the ...

View the full article

sponsored ad

  • Advert

#364 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 December 2013 - 02:15 PM

Vista Partners Publishes December 2013 Macroeconomic & Investment Newsletter
Wall Street Journal - 3 hours ago
Tec Limited, Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), BioTime, Inc., Redhawk Resources, Inc., The Alkaline Water Company Inc. Targeted Medical Pharma Inc., and Power Solutions International Inc. (NASDAQ: PSIX).

View the full article

#365 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 December 2013 - 09:11 PM

BioTime, Inc. : LifeMap Sciences, a Subsidiary of BioTime, Announces Release ...
4-traders (press release) - 4 minutes ago
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.11.

View the full article

#366 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 December 2013 - 09:11 PM

BioTime, Inc. : LifeMap Sciences, a Subsidiary of BioTime, Announces Release ...
4-traders (press release) - 3 hours ago
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.11.
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards ... - HispanicBusiness.com

View the full article

#367 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 04 December 2013 - 01:52 PM

BioTime, Inc. : BioTime's CEO, Dr. Michael West to Moderate Session on ...
4-traders (press release) - Dec 4, 2013
BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr. Michael West will lead a session titled "From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative" today at the ...

View the full article

#368 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 December 2013 - 02:15 PM

Vista Partners Publishes December 2013 Macroeconomic & Investment Newsletter
Wall Street Journal - Dec 6, 2013
Tec Limited, Ohr Pharmaceutical, Inc. (NASDAQ: OHRP), BioTime, Inc., Redhawk Resources, Inc., The Alkaline Water Company Inc. Targeted Medical Pharma Inc., and Power Solutions International Inc. (NASDAQ: PSIX).

View the full article

#369 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 04 December 2013 - 01:52 PM

BioTime's CEO, Dr. Michael West to Moderate Session on Mapping the Cellular ...
HispanicBusiness.com - Dec 4, 2013
ALAMEDA, Calif. --(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr.

View the full article

#370 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 11 December 2013 - 08:15 AM

California's Stem-Cell Quest Races Time as Money Dwindles
Bloomberg - 8 hours ago
Geron later sold its stem-cell program for $35 million in cash and stock to Alameda, California-based Biotime Inc. (BTX). Nevertheless, the stem-cell agency's go-commercial push is warranted, said Hank Greely, a professor specializing in biomedical ...

View the full article

#371 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 12 December 2013 - 03:45 PM

3 Reasons Behind Geron Corporation (GERN)'s Rebound
Next iPhone News - Dec 12, 2013
In October 2013, Geron sold its entire embryonic stem cell pipeline to BioTime, Inc. (NYSEMKT:BTX)'s new subsidiary Asterias Biotherapeutics, in exchange for a 21.4% stake in Asterias and undisclosed royalties on commercialized treatments ...

View the full article

#372 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 11 December 2013 - 08:15 AM

California's $3 Billion Stem-Cell Quest Races as Money Dwindles
Businessweek - Dec 11, 2013
Geron later sold its stem-cell program for $35 million in cash and stock to Alameda, California-based Biotime Inc. (BTX:US).

View the full article

#373 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 17 December 2013 - 03:22 PM

Is Geron Corporation (GERN) Finally Onto Something?
Next iPhone News - 57 minutes ago
Geron Corporation (NASDAQ:GERN) has continued reshaping itself this year by closing a deal to sell its human embryonic stem cell assets to BioTime, Inc. (NYSEMKT:BTX), and closing its research facility in California last April. To save money, Geron ...

View the full article

#374 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 20 December 2013 - 02:03 PM

BioTime, Inc. : BioTime Reports Isolation of Novel Brain-Associated Cells From ...
4-traders (press release) - 16 minutes ago
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers ...

View the full article

#375 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 20 December 2013 - 02:03 PM

BioTime, Inc. : BioTime Reports Isolation of Novel Brain-Associated Cells From ...
4-traders (press release) - 10 hours ago
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers ...

View the full article

#376 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 23 December 2013 - 01:52 PM

BioTime, Inc. : BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 ...
4-traders (press release) - 1 hour ago
23, 2013-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million) from Israel's Office of the Chief ...
BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant ... - Business Wire (press release)

View the full article

#377 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 20 December 2013 - 02:03 PM

BioTime, Inc. : BioTime Reports Isolation of Novel Brain-Associated Cells From ...
4-traders (press release) - Dec 20, 2013
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers ...

View the full article

#378 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 02 December 2013 - 03:56 PM

BioTime (BTX) Trades Flat Amid $15M Equity Offering
StreetInsider.com (subscription) - Dec 2, 2013
BioTime, Inc. (NYSE: BTX) is flat amid news the company filed a registration statement with the SEC or an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right.

View the full article

#379 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 31 December 2013 - 05:48 AM

BioTime, Inc. : BioTime Reports Publication of Peer-reviewed Scientific Paper
4-traders (press release) - 3 hours ago
BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, reported the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers of particular cell ...

View the full article

#380 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 31 December 2013 - 05:15 PM

Insider Buying: Neal Bradsher Acquires 300042 Shares of BioTime Stock (BTX)
Ticker Report - 2 hours ago
BioTime Inc. logo BioTime (NYSE:BTX) Director Neal Bradsher bought 300,042 shares of the company's stock on the open market in a transaction dated Monday, December 30th.

View the full article

#381 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 31 December 2013 - 05:58 AM

BioTime, Inc. : BioTime Reports Publication of Peer-reviewed Scientific Paper
4-traders (press release) - 17 hours ago
BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, reported the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers of particular cell ...

View the full article

#382 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 31 December 2013 - 05:58 AM

BioTime, Inc. : BioTime Reports Publication of Peer-reviewed Scientific Paper
4-traders (press release) - Dec 31, 2013
BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, reported the publication of a peer-reviewed scientific paper on the successful generation of human cells with markers of particular cell ...

View the full article

#383 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 02 January 2014 - 01:52 PM

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases ...
Business Wire (press release) - 3 hours ago
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) today announced that Asterias has executed a long term lease for a research, development and manufacturing facility to house ...

View the full article

#384 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 30 December 2013 - 10:30 AM

BioTime, Inc. : Regenerative Medicine to Publish Paper on BioTime's Isolation ...
4-traders (press release) - Dec 30, 2013
BioTime, Inc. , a biotechnology company that develops and markets products in the field of regenerative medicine, reported the publication of a peer-reviewed scientific paper in Regenerative Medicine on the generation of human cells with markers of ...

View the full article

#385 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 04 January 2014 - 10:30 AM

Asterias leases facilities for product R&D, manufacturing
pharmabiz.com - 50 minutes ago
Asterias Biotherapeutics, Inc. a subsidiary of BioTime, Inc., has executed a long term lease for a research, development and manufacturing facility to house all of its cell therapy product development activities.
Asterias Biotherapeutics leases facilities for expanded product development ... - Pharmaceutical Business Review

View the full article

#386 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 05 January 2014 - 02:37 PM

Forecast 2014: The Human Transformation Revolution
Gold Seek - 7 hours ago
This is why my colleague Patrick Cox (who writes our Transformational Technology Alert letter) and I volunteered to participate in a pilot project conducted by BioTime, Inc. We both donated cells taken from inside our left arms. Those cells were then ...

View the full article

#387 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 January 2014 - 05:37 AM

BioTime, Inc. : BioTime's Subsidiary Cell Cure Neurosciences Receives Grant ...
4-traders (press release) - 3 hours ago
BioTime, Inc. and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million ) from Israel's Office of the Chief Scientist (OCS) to help finance ...

View the full article

#388 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 02 January 2014 - 01:52 PM

Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases ...
Business Wire (press release) - Jan 2, 2014
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) today announced that Asterias has executed a long term lease for a research, development and manufacturing facility to house ...

View the full article

#389 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 06 January 2014 - 05:37 AM

BioTime, Inc. : BioTime's Subsidiary Cell Cure Neurosciences Gets Grant from ...
4-traders (press release) - Jan 6, 2014
BioTime, Inc. and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) announced that Cell Cure has been awarded a grant for 2014 of 6.1 million Shekels (approximately $1.74 million ) from Israel's Office of the Chief Scientist (OCS) to help finance ...

View the full article

#390 ImmInst

  • Admin, Director robot
  • 2,357 posts
  • 73

Posted 13 January 2014 - 02:03 PM

BioTime Reports Results of Clinical Safety Trial of Renevia™
Wall Street Journal - 1 hour ago
BioTime, Inc. (NYSE MKT: BTX) today announced the completion of a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, and the results of that study.

View the full article





Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

2 user(s) are reading this topic

0 members, 2 guests, 0 anonymous users